Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

SRR6013520

· cohortA1

132797dd-abf2-55fa-8a33-1229f438d783

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
cohortA1
subtype
cohortA1

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.190
  • MITOTIC_SPINDLE+0.120
  • UV_RESPONSE_DN+0.040
  • APICAL_SURFACE+0.010
  • MYOGENESIS+0.000
  • SPERMATOGENESIS+0.000
  • KRAS_SIGNALING_UP-0.030
  • BILE_ACID_METABOLISM-0.040
  • HEDGEHOG_SIGNALING-0.040
  • PANCREAS_BETA_CELLS-0.040

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.630
  • MYC_TARGETS_V1-0.600
  • MTORC1_SIGNALING-0.510
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.510
  • UNFOLDED_PROTEIN_RESPONSE-0.470
  • E2F_TARGETS-0.450
  • GLYCOLYSIS-0.420
  • PROTEIN_SECRETION-0.410
  • G2M_CHECKPOINT-0.370
  • ADIPOGENESIS-0.350

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR11296737
colon-landscapes@1
0.924
2SRR1516040
bladder-landscape@3
0.921
3TCGA-CU-A3YL-01A-11R-A22U-07
bladder-landscape@3
0.916
4SRR934787
brain-umap@2
0.912
5ERR4976613
breast-umap@18
D0.904
6BS_4GTESTSE
brain-umap@2
Ganglioglioma0.903
7MNG1217
mng-umap@100
0.903
8BS_YNEQJ6AH
brain-umap@2
DNET0.901
9MNG786
mng-umap@100
0.899
1020040121.LumB
breast-umap@18
D0.899

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 4 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.190Remibrutinib— uncovered
MITOTIC_SPINDLE0.120Inavolisib— uncovered
UV_RESPONSE_DN0.040Inavolisib— uncovered
APICAL_SURFACE0.010Temsirolimus— uncovered